» Articles » PMID: 8764076

Transcriptional Activation of a Retrovirus Enhancer by CBF (AML1) Requires a Second Factor: Evidence for Cooperativity with C-Myb

Overview
Journal J Virol
Date 1996 Aug 1
PMID 8764076
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Transcriptional enhancer sequences within the long terminal repeats (LTRs) of murine leukemia viruses are the primary genetic determinants of the tissue specificity and potency of the oncogenic potential of these retroviruses. SL3-3 (SL3) is a murine leukemia virus that induces T-cell lymphomas. The LTR enhancer of this virus contains two binding sites for the transcription factor CBF (also called AML1 and PEBP2) that flank binding sites for c-Myb and the Ets family of factors. Using cotransfection assays in P19 cells, we report here that CBF and c-Myb cooperatively stimulate transcription from the SL3 LTR. By itself, c-Myb had no stimulatory effect on transcription. However, when cotransfected with a cDNA encoding one form of the alpha subunit of CBF called CBFalpha2-451, a level of transactivation higher than that seen with CBFalpha2-451 alone was detected. The negative regulatory domain near the carboxyl terminus of c-Myb did not affect this activity. Electrophoretic mobility shift assays indicated that CBF and c-Myb bind to DNA independently. Therefore, it appears that the cooperative stimulation of transcription by these factors occurs at a step in the process of transcription after the two factors are bound to the enhancer. Sequences near the carboxyl terminus of CBFalpha2-451 were important for cooperativity with c-Myb, consistent with previous reports that this region contains an activation domain. However, CBFalpha2-451 failed to activate transcription from a version of the SL3 LTR in which the enhancer was replaced with five tandem CBF-binding sites. Thus, it appears that transcriptional activation of the SL3 enhancer by CBF requires that an appropriate heterologous transcription factor be bound to a neighboring site in the regulatory sequences.

Citing Articles

A unifying gene signature for adenoid cystic cancer identifies parallel MYB-dependent and MYB-independent therapeutic targets.

Gao R, Cao C, Zhang M, Lopez M, Yan Y, Chen Z Oncotarget. 2015; 5(24):12528-42.

PMID: 25587024 PMC: 4350357. DOI: 10.18632/oncotarget.2985.


SARS coronavirus 3b accessory protein modulates transcriptional activity of RUNX1b.

Varshney B, Agnihothram S, Agnihotram S, Tan Y, Baric R, Lal S PLoS One. 2012; 7(1):e29542.

PMID: 22253733 PMC: 3257236. DOI: 10.1371/journal.pone.0029542.


Control of pathogenicity and disease specificity of a T-lymphomagenic gammaretrovirus by E-box motifs but not by an overlapping glucocorticoid response element.

Ejegod D, Sorensen K, Mossbrugger I, Quintanilla-Martinez L, Schmidt J, Pedersen F J Virol. 2008; 83(1):336-46.

PMID: 18945767 PMC: 2612299. DOI: 10.1128/JVI.01368-08.


RUNX1 permits E4orf6-directed nuclear localization of the adenovirus E1B-55K protein and associates with centers of viral DNA and RNA synthesis.

Marshall L, Moore A, Ohki M, Kitabayashi I, Patterson D, Ornelles D J Virol. 2008; 82(13):6395-408.

PMID: 18417565 PMC: 2447068. DOI: 10.1128/JVI.00043-08.


Mutation of all Runx (AML1/core) sites in the enhancer of T-lymphomagenic SL3-3 murine leukemia virus unmasks a significant potential for myeloid leukemia induction and favors enhancer evolution toward induction of other disease patterns.

Sorensen K, Quintanilla-Martinez L, Kunder S, Schmidt J, Pedersen F J Virol. 2004; 78(23):13216-31.

PMID: 15542674 PMC: 524987. DOI: 10.1128/JVI.78.23.13216-13231.2004.


References
1.
Janknecht R, Nordheim A . Gene regulation by Ets proteins. Biochim Biophys Acta. 1993; 1155(3):346-56. DOI: 10.1016/0304-419x(93)90014-4. View

2.
Kagoshima H, Shigesada K, Satake M, Ito Y, Miyoshi H, Ohki M . The Runt domain identifies a new family of heteromeric transcriptional regulators. Trends Genet. 1993; 9(10):338-41. DOI: 10.1016/0168-9525(93)90026-e. View

3.
Yamamoto K, Tojo A, Aoki N, Shibuya M . Characterization of the promoter region of the human c-kit proto-oncogene. Jpn J Cancer Res. 1993; 84(11):1136-44. PMC: 5919084. DOI: 10.1111/j.1349-7006.1993.tb02813.x. View

4.
Mitani K, Ogawa S, Tanaka T, Miyoshi H, Kurokawa M, Mano H . Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J. 1994; 13(3):504-10. PMC: 394839. DOI: 10.1002/j.1460-2075.1994.tb06288.x. View

5.
Bae S, Ogawa E, Maruyama M, Oka H, Satake M, Shigesada K . PEBP2 alpha B/mouse AML1 consists of multiple isoforms that possess differential transactivation potentials. Mol Cell Biol. 1994; 14(5):3242-52. PMC: 358691. DOI: 10.1128/mcb.14.5.3242-3252.1994. View